Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

Summary: Background: Biologics directed against the T-helper (Th)-17 pathway have been approved for several inflammatory diseases. Interleukin (IL)-17 is involved in anti-Candida host defense, and clinical trials suggested increased candidiasis incidence during IL-17 inhibitor therapy. We describe...

Full description

Bibliographic Details
Main Authors: Linda Davidson, Juul M.P.A. van den Reek, Mariolina Bruno, Florence van Hunsel, Ron M.C. Herings, Vasiliki Matzaraki, Collins K. Boahen, Vinod Kumar, Hans M.M. Groenewoud, Frank L. van de Veerdonk, Mihai G. Netea, Elke M.G.J. de Jong, Bart Jan Kullberg
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:The Lancet Regional Health. Europe
Subjects:
Candidiasis
IL-17 inhibitors
IL-12/23 inhibitors
Drug safety
Pharmacovigilance
ustekinumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776221002520

Internet

http://www.sciencedirect.com/science/article/pii/S2666776221002520

Similar Items